



Atty. Docket No.: PG3416US2

In the Claims:

A complete listing of claims 1-36 with status identifier follows.

Claim 1 (Currently Amended): A compound of the formula:



and salts or solvates thereof.

Claim 2 (Original): A pharmaceutical formulation, comprising: the compound of claim 1 or a pharmaceutically acceptable salt or solvate thereof together with one or more pharmaceutically acceptable carriers, diluents, or excipients.

Claim 3 (Currently Amended): A method of treating a susceptible cancer in a human or animal subject mammal, comprising administering to said subject an effective amount of a compound as claimed in claim 1, wherein said cancer is breast cancer, gastric cancer or head and neck cancer.

B

Atty. Docket No.: PG3416US2

Claim 4 (Currently Amended): A method as claimed in claim 3, wherein the susceptible cancer is ~~a susceptible~~ breast cancer.

Claims 5-6 (Cancelled)

Claim ⁵7 (Currently Amended): A method as claimed in claim 3, wherein the susceptible cancer is ~~a susceptible stomach~~ gastric cancer.

Claim 8 (Cancelled)


Claim ⁸9 (Currently Amended): A method as claimed in claim 3, wherein the susceptible cancer is ~~a susceptible~~ head and neck cancer.

~~Claim 10 (Currently Amended): A method as claimed in claim 3, wherein the susceptible cancer is ~~a susceptible cancer~~ characterized by expression or over-expression of EGFR.~~


~~Claim 11 (Currently Amended): A method as claimed in claim 3, wherein the susceptible cancer is ~~a susceptible cancer~~ characterized by expression or over-expression of erbB-2.~~

~~Claim 12 (Currently Amended): A ¹²method as claimed in claim 3, wherein the susceptible cancer is ~~a susceptible cancer~~ characterized by expression or over-expression of EGFR and erbB-2.~~

Claim ¹²13 (Currently Amended): A compound of the formula:



Atty. Docket No.: PG3416US2



and salts or solvates thereof.

Claim ⁸~~14~~ (Previously Presented): A pharmaceutical formulation, comprising: the compound of claim ~~13~~ or a pharmaceutically acceptable salt or solvate thereof together with one or more pharmaceutically acceptable carriers, diluents, or excipients.

B¹ Claim ⁹~~15~~ (Currently Amended): A method of treating a susceptible cancer in a human or animal subject mammal, comprising administering to said subject an effective amount of a compound as claimed in claim ~~13~~, wherein said cancer is breast cancer, gastric cancer or head and neck cancer.

Claim ¹⁰~~16~~ (Currently Amended): A method as claimed in claim ⁹~~15~~, wherein the susceptible cancer is a ~~susceptible~~ breast cancer.

Claims 17-18 (Cancelled)

Claim ¹¹~~19~~ (Currently Amended): A method as claimed in claim ⁹~~15~~, wherein the susceptible cancer is a ~~susceptible stomach~~ gastric cancer.

Claim 20 (Cancelled)

Claim ¹²~~21~~ (Currently Amended): A method as claimed in claim ⁹~~15~~, wherein the susceptible cancer is a ~~susceptible~~ head and neck cancer.

B


Atty. Docket No.: PG3416US2

~~Claim 22 (Currently Amended): A method as claimed in claim 1615, wherein the susceptible cancer is a susceptible cancer characterized by expression or over-expression of EGFR.~~

~~Claim 23 (Currently Amended): A method as claimed in claim 1615, wherein the susceptible cancer is a susceptible cancer characterized by expression or over-expression of erbB-2.~~

~~Claim 24 (Currently Amended): A method as claimed in claim 1615, wherein the susceptible cancer is a susceptible cancer characterized by expression or over-expression of EGFR and erbB-2.~~

~~Claim 25 (Currently Amended): A compound of the formula:~~



and salts or solvates thereof.

~~Claim 26 (Previously Presented): A pharmaceutical formulation, comprising: the compound of claim 25 or a pharmaceutically acceptable salt or solvate thereof together with one or more pharmaceutically acceptable carriers, diluents, or excipients.~~

Atty. Docket No.: PG3416US2

¹⁵
Claim ~~27~~ (Currently Amended): A method of treating a susceptible cancer in a human or animal subject mammal, comprising administering to said subject an effective amount of a compound as claimed in claim ¹³~~25~~, wherein said cancer is breast cancer, gastric cancer or head and neck cancer.

¹⁶
Claim ~~28~~ (Currently Amended): A method as claimed in claim ¹⁵~~27~~, wherein the susceptible cancer is ~~a-susceptible~~ breast cancer.

☒ Claims 29-30 (Cancelled)

¹⁷
Claim ~~31~~ (Currently Amended): A method as claimed in claim ¹⁵~~27~~, wherein the susceptible cancer is ~~a-susceptible stomach~~ gastric cancer.

☒ Claim 32 (Cancelled)

¹⁸
Claim ~~33~~ (Currently Amended): A method as claimed in claim ¹⁵~~27~~, wherein the susceptible cancer is ~~a-susceptible~~ head and neck cancer.

~~Claim 34 (Currently Amended): A method as claimed in claim 27, wherein the susceptible cancer is a-susceptible cancer characterized by expression or over-expression of EGFR.~~

~~Claim 35 (Currently Amended): A method as claimed in claim 27, wherein the susceptible cancer is a-susceptible cancer characterized by expression or over-expression of erbB-2.~~

~~Claim 36 (Currently Amended): A method as claimed in claim 27, wherein the susceptible cancer is a-susceptible cancer characterized by expression or over-expression of EGFR and erbB-2.~~